Results 81 to 90 of about 22,516 (228)

Real‐World Overall Survival With Abiraterone Acetate and Enzalutamide in Patients With Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer From the Flatiron Electronic Health Records Database

Cancer Medicine, Volume 15, Issue 10, October 2026.
This real‐world study of the Flatiron Health database found that first‐line treatment with abiraterone versus enzalutamide was associated with significantly shorter overall survival, treatment duration, and time to subsequent treatment in patients with chemotherapy‐ and androgen receptor pathway inhibitor‐naïve metastatic castration‐resistant prostate ...
Daniel J. George, Jasmina I. Ivanova, Maëlys Touya, Betty Thompson, Jonathan Assayag, Benjamin Li, Nikolaos Kountouris, Gordon Siu, Stephen J. Freedland   +8 more
wiley   +1 more source

NFYA-mediated promotion of castration-resistant prostate cancer progression through EGR4 regulation

Discover Oncology
This research investigates the intricate involvement of nuclear Transcription Factor Y Subunit Alpha (NFYA) in the advancement of castration-resistant prostate cancer (CRPC) and its consequential impact on early Growth Response 4 (EGR4) expression.
Guijiang Sun, Yi Shao, Qianwang Ma, Shengju Song, Yutong Chen, Yang Li, Yue Gao, Haitao Wang, Zhiqun Shang   +8 more
doaj   +1 more source

Skin‐Related Adverse Events in Patients Treated With Apalutamide Versus Enzalutamide for Prostate Cancer: A Japanese Real‐World Database Study (A Retrospective Cohort Study)

Health Science Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background and Aims Apalutamide (APA) and enzalutamide (ENZ) are androgen receptor pathway inhibitors widely used for prostate cancer. Skin rash is a characteristic adverse event of APA, but how often it occurs in real‐world practice, the factors related to it, and possible differences by disease stage are not well understood.
Akihito Hashizume, Takashi Kawahara, Masanobu Yamazaki, Daiji Takamoto, Teppei Takeshima, Shinnosuke Kuroda, Hiroji Uemura, Kazuhide Makiyama, Jun‐Ichi Teranishi   +8 more
wiley   +1 more source

Expression of AR variants and AR regulated proteins in metastatic CRPC.

, 2013
(A) IHC staining for N-terminal AR (a), C-terminal AR (b), PSA (c), PSMA (d), TMPRSS2 (e), AKT-1 (f), Ki-67(g), Negative control (h) on a metastatic CRPC tissue (magnification x200, insert x400). (B) PSA, PSMA, TMPRSS2 and AKT-1 staining profiles of CRPC.
Colm Morrissey (35516), Lawrence D. True (339279), Shihua Sun (339277), Melanie Ketchandji (339278), Peter S. Nelson (167711), Funda Vakar-Lopez (242696), Stephen R. Plymate (242698), Robert L. Vessella (200698), Xiaotun Zhang (339276)   +8 more
core   +1 more source

KDM3B suppresses castration-resistance prostate cancer cell proliferation by promoting PTEN expression

European Journal of Medical Research
Background Castration-resistant prostate cancer (CRPC) represents the terminal stage of prostate cancer (PCa), yet the molecular mechanisms driving its development remain unclear.
Pengfei Zhang, Yifan Liu, Liangming Pan, Junjie Ma, Xi Chen, Yuntao Wu   +5 more
doaj   +1 more source

Molecular mechanisms and classification of castration-resistant prostate cancer: Insights into androgen receptor, cancer stem cells, and neuroendocrine features

Current Urology
. Castration-resistant prostate cancer (CRPC) is a considerable clinical challenge, driven by complex molecular mechanisms that enable tumors to evade androgen deprivation therapy.
Yuan Shao, Zihao Liu, Jialu Ma, Yuankang Feng, Jianpeng Yu, Hua Huang, Yang Liu, Yuanjie Niu, Yong Wang   +8 more
doaj   +1 more source

Longitudinally Monitoring Prostate Cancer Bone Metastasis and Treatment Response via Circulating Extracellular Vesicles

Journal of Extracellular Vesicles, Volume 15, Issue 10, October 2026.
ABSTRACT Lethal prostate cancer (PCa) is dominated by treatment‐refractory progression in bone. In this study, we used plasma‐derived extracellular vesicles (EVs) for monitoring the tumour and therapy‐induced changes in the bone tumour microenvironment (bone‐TME) in men with bone metastatic PCa (M1b PCa).
Emanuela Gentile, Paul G. Corn, Martha Zavridou, James P. Long, Jian H. Song, Anh Hoang, Andrew W. Hahn, Eleonora Dondossola, William Norton, Sue‐Hwa Lin, Christopher J. Logothetis, Theocharis Panaretakis   +11 more
wiley   +1 more source

Silencing of matrix metalloprotease-12 delays the progression of castration-resistant prostate cancer by regulating autophagy and lipolysis [PDF]

Brazilian Journal of Medical and Biological Research
The complex pathogenesis of castration-resistant prostate cancer (CRPC) makes it challenging to identify effective treatment methods. Matrix metalloproteinase (MMP)-12 can degrade elastin as well as various extracellular matrix (ECM) components, which is
Xiaoyu Zheng, Xiaoqin Xie, Wei Wang, Liang Wang, Bing Tan   +4 more
doaj   +1 more source

Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of ‘‐mabs’?

The Journal of Pathology, Volume 270, Issue 2, Page 139-162, October 2026.
Abstract Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone‐sensitive PCa to metastatic castration‐resistant PCa.
Giuseppe Schepisi, Irene Torresan, Emilio Francesco Giunta, Sara Bleve, Nicole Brighi, Elisa Tassinari, Sofia Zanuccoli, Maria Concetta Cursano, Cristian Lolli   +8 more
wiley   +1 more source

Novel biomarker of specific castration-resistant prostate cancer (CRPC) by exploring the proteome analysis.

, 2017
247 Background: It is well known that prostate specific antigen (PSA) level has no reliable correlation with pathological malignancy of prostate cancer and is not a predictor for the development of castration resistant prostate cancer (CRPC).
Norihisa Ohtake, Noriaki Arakawa, Hiroji Uemura, Yusuke Itoh, Yasuhide Miyoshi, Shouhei Akiba, Takashi Kawahara   +6 more
core   +1 more source